esophageal cancer peptide specific ctl
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT03011255)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- esophageal cancer peptide specific ctl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03011255 | Phase 2 | Dec 1, 2016 | Chinese Academy of Medical Sciences, Hangzhou Cancer Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Hangzhou Cancer Hospital | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1